Lung cancer is the most frequently diagnosed cancer globally and the primary cause of cancer-related mortality. The increasing research and clinical application of immune checkpoint inhibitors (ICIs) have led to significant progress in the treatment of advanced lung cancer. This article provides a comprehensive review of the mechanism of action, therapeutic applications, and adverse reactions of sintilimab, a domestically developed PD-1 inhibitor, to offer insights for future research and clinical practices.

Yang Yang, Gong Jianhua. Research Progress of Sintilimab in Advanced Non-Small Cell Lung Cancer. Frontiers in Medical Science Research (2025), Vol. 7, Issue 5: 89-94. https://doi.org/10.25236/FMSR.2025.070510.

[1] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. Journal of the National Cancer Center, 2024, 4(1): 47–53.

[2] Socinski M A, Obasaju C, Gandara D, et al. Clinicopathologic Features of Advanced Squamous NSCLC[J]. Journal of Thoracic Oncology, 2016, 11(9): 1411–1422.

[3] Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review[J]. Frontiers in Immunology, 2023, 14.

[4] Thai A A, Solomon B J, Sequist L V, et al. Lung cancer[J]. The Lancet, 2021, 398(10299): 535–554.

[5] Sun C, Mezzadra R, Schumacher T N. Regulation and Function of the PD-L1 Checkpoint[J]. Immunity, 2018, 48(3): 434–452.

[6] Rad H S, Monkman J, Warkiani M E, et al. Understanding the tumor microenvironment for effective immunotherapy[J]. Medicinal Research Reviews, 2020, 41(3): 1474–1498.

[7] Liu X, Yi Y. Recent updates on Sintilimab in solid tumor immunotherapy[J]. Biomarker Research, 2020, 8(1).

[8] Zhang L, Mai W, Jiang W, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody[J]. Frontiers in Oncology, 2020, 10.

[9] Zhou C, Wu L, Fan Y, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)[J]. Journal of Thoracic Oncology, 2021, 16(9): 1501–1511.

[10] Yang Y, Wang Z, Fang J, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)[J]. Journal of Thoracic Oncology, 2020, 15(10): 1636–1646.

[11] Liu T, He J, Wang Y, et al. Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-bli[J]. Lung Cancer, 2025, 200: 108108.

[12] Pan L, Chen Q, Liang N, et al. Meta-Analysis of the Efficacy and Safety of Sintilimab in Combination With Chemotherapy for Advanced Non–Small-Cell Lung Cancer[J]. Current Therapeutic Research, 2025, 103: 100796.

[13] Zhang L, Qian Y, Li J, et al. Indirect Comparison of Sintilimab and Other PD-L1 Inhibitors for First-Line Treatment of Non-Squamous Non-Small-Cell Lung Cancer[J]. Future Oncology, 2022, 18(15): 1896–1905.

[14] Wang J, Fei K, Jing H, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit[J]. mAbs, 2019, 11(8): 1443–1451.

[15] Liu S-Y M, Huang J, Deng J-Y, et al. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial[J]. Science Bulletin, 2024, 69(4): 535–543.

[16] Li F, Chen Y, Xiao D, et al. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective[J]. Advances in Therapy, 2024, 41(4): 1436–1449.

[17] Csiki E, Simon M, Papp J, et al. Stereotactic body radiotherapy in lung cancer: a contemporary review[J]. Pathology and Oncology Research, 2024, 30.

[18] Zhou X, Zhou L, Yao Z, et al. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients[J].  Clinical Cancer Research, 2023, 29(20): 4098–4108.

[19] Mehta H M, Malandra M, Corey S J. G-CSF and GM-CSF in Neutropenia[J]. The Journal of Immunology, 2015, 195(4): 1341–1349.

[20] Ni J, Wang X, Wu L, et al. Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial[J]. Nature Communications, 2024, 15(1).

[21] Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. Journal of Hematology & Oncology, 2018, 11(1).

[22] Yang Y, Li L, Jiang Z, et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer[J]. Cancer Immunology, Immunotherapy, 2020, 69(12): 2523–2532.

[23] Chu T, Zhong H, Yu Z, et al. Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial[J]. Cancer Communications, 2025, 45(4): 442–455.

[24] Lin M, Luo H, Liang S, et al. Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients[J]. Journal of Clinical Investigation, 2020, 130(5): 2560–2569.

[25] Jia L, Chen N, Chen X, et al. Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy[J]. Frontiers in Immunology, 2022, 13.

[26] Jia L, Chen N, Chen X, et al. Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer[J]. Frontiers in Immunology, 2025, 16.

[27] Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-bli[J]. The Lancet Oncology, 2022, 23(9): 1167–1179.

[28] Freites-Martinez A, Santana N, Arias-Santiago S, et al. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas[J]. Actas Dermo-Sifiliográficas, 2021, 112(1): 90–92.

[29] Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.[J]. Translational lung cancer research, 2015.

[30] Zhao P, Zhao T, Yu L, et al. The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis[J]. Frontiers in Oncology, 2024, 14.

[31] Xie J, Wu X, Wu J, et al. Meta analysis of the efficacy and safety of sintilimab for treating advanced non small cell lung cancer[J]. Oncology Letters, 2022, 24(6).